Literature DB >> 19309274

Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Mary S Beattie1, Beth Crawford, Feng Lin, Eric Vittinghoff, John Ziegler.   

Abstract

INTRODUCTION AND AIMS: For women who carry BRCA mutations, risk-reducing surgeries are an option to decrease breast and ovarian cancer risk. This study aims to determine the uptake, time course, and predictors of risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) in BRCA carriers.
RESULTS: In 272 female carriers, followed for a median of 3.7 years, 23% of those eligible chose RRM, and 51% percent chose RRSO. Among BRCA carriers who chose these procedures, median time to both RRM and RRSO was approximately 4 months after learning of BRCA-positive results. Predictors of RRM were as follows: age below 60 years (hazard ratio 1.8, p=0.04), prior breast cancer (hazard ratio 2.4, p=0.0004), and RRSO (hazard ratio 7.2, p<0.0001). Predictors of RRSO were as follows: age below 60 years (hazard ratio 3.6, p=0.006), prior breast cancer (hazard ratio 1.8, p=0.002), and RRM (hazard ratio 5.4, p<0.0001).
CONCLUSIONS: Many women who undergo BRCA testing use these results to make clinical decisions; those who choose risk-reducing surgeries typically do so within months of receiving BRCA-positive results. Predictors of risk-reducing surgery uptake include the following: age below 60 years, prior breast cancer, and utilization of another risk-reducing surgery. Future research directions include examining other preventive and screening options in BRCA carriers as well as studying motivations for choosing or declining risk-reducing surgeries.

Entities:  

Mesh:

Year:  2009        PMID: 19309274      PMCID: PMC2981359          DOI: 10.1089/gtmb.2008.0067

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  36 in total

1.  Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.

Authors:  Robin Lee; Mary Beattie; Beth Crawford; Julie Mak; Nicola Stewart; Miriam Komaromy; Laura Esserman; Lucille Shaw; Jane McLennan; Lori Strachowski; Judy Luce; John Ziegler
Journal:  Genet Test       Date:  2005

2.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.

Authors:  A S Whittemore; G Gong; J Itnyre
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

Review 3.  Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.

Authors:  Sara Wainberg; Janice Husted
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-12       Impact factor: 4.254

Review 4.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Laurie Hoyt Huffman; Rongwei Fu; Emily L Harris
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

5.  Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Authors:  E Levy-Lahad; R Catane; S Eisenberg; B Kaufman; G Hornreich; E Lishinsky; M Shohat; B L Weber; U Beller; A Lahad; D Halle
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Authors:  C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.

Authors:  Noah D Kauff; Karen E Hurley; Martee L Hensley; Mark E Robson; Gali Lev; Deborah Goldfrank; Mercedes Castiel; Carol L Brown; Jamie S Ostroff; Lucy E Hann; Kenneth Offit; Richard R Barakat
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

9.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

Authors:  C Bethan Powell; Eric Kenley; Lee-May Chen; Beth Crawford; Jane McLennan; Charles Zaloudek; Miriam Komaromy; Mary Beattie; John Ziegler
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

10.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

View more
  29 in total

1.  Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.

Authors:  Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal
Journal:  Cancer       Date:  2017-02-09       Impact factor: 6.860

2.  Heightened perception of breast cancer risk in young women at risk of familial breast cancer.

Authors:  Rachael Glassey; Moira O'Connor; Angela Ives; Christobel Saunders; Sarah O'Sullivan; Sarah J Hardcastle
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

3.  Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Authors:  Dongwon Kim; Eunyoung Kang; Euijun Hwang; Young Sun; Yoonsun Hwang; Cha Kyong Yom; Kidong Kim; Jae Hong No; Yong-Beom Kim; Sung-Won Kim
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

4.  Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Authors:  Xinglei Chai; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Peter J Hulick; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joanne L Blum; Susan M Domchek; Jinbo Chen; Timothy R Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2014-10-14       Impact factor: 4.872

5.  Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.

Authors:  Se Ik Kim; Myong Cheol Lim; Dong Ock Lee; Sun-Young Kong; Sang-Soo Seo; Sokbom Kang; Eun Sook Lee; Sang-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-05       Impact factor: 4.553

6.  Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.

Authors:  Stephanie Kearton; Karen Wills; Michael Bunting; Penny Blomfield; Paul A James; Jo Burke
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

7.  Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Authors:  Mark H Greene; Phuong L Mai; Peter E Schwartz
Journal:  Am J Obstet Gynecol       Date:  2010-07-08       Impact factor: 8.661

8.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

9.  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

Authors:  Gabriel N Mannis; Julia E Fehniger; Jennifer S Creasman; Vanessa L Jacoby; Mary S Beattie
Journal:  JAMA Intern Med       Date:  2013-01-28       Impact factor: 21.873

10.  The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.

Authors:  Charles W Drescher; J David Beatty; Robert Resta; M Robyn Andersen; Kate Watabayashi; Jason Thorpe; Sarah Hawley; Hannah Purkey; Jessica Chubak; Nancy Hanson; Diana S M Buist; Nicole Urban
Journal:  Cancer       Date:  2016-07-22       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.